34 studies found for:    " May 23, 2012":" June 22, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
1 Completed An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients
Condition: Human Immunodeficiency Virus (HIV)
Interventions: Drug: darunavir (PREZISTA);   Drug: etravirine (INTELENCE);   Drug: ritonavir;   Drug: Other antiretroviral medications
2 Recruiting Peer-driven Intervention to Seek, Test & Treat Heterosexuals at High Risk for HIV
Conditions: HIV/AIDS;   Vulnerable Populations;   Heterosexuals at High Risk
Interventions: Behavioral: BCAP peer-driven intervention (PDI);   Behavioral: Control intervention
3 Enrolling by invitation Observational Study of HIV Infection in Participants of Seroconvert During Dapivirine Vaginal Ring Trials
Condition: HIV Infections
Intervention: Drug: No Investigational Product
4 Recruiting Phase 3 Safety and Effectiveness Trial of Dapivirine Vaginal Ring for Prevention of HIV-1 in Women
Condition: HIV Infections
Interventions: Drug: Dapivirine;   Drug: Placebo
5 Active, not recruiting Evaluation of Behavioral Intervention for HIV Positive Prisoners in NC and TX
Condition: HIV Infection
Interventions: Behavioral: Text reminders, counseling, and link coordination;   Behavioral: Standard of care - control arm
6 Recruiting Alcohol's Impact on Inflammatory Markers in HIV Disease - Russia ARCH Cohort
Conditions: HIV Infection;   Alcohol Use
Intervention:
7 Completed Study to Optimize the Quality of Samples for Cell-mediated Immunity (CMI) in ART-naïve HIV-1-infected Subjects
Condition: HIV Infection
Intervention: Procedure: Blood sample collection
8 Unknown  Antiretroviral Adherence Evaluation in HIV Pregnant and Postpartum Women
Conditions: HIV Infection;   Pregnancy
Intervention:
9 Active, not recruiting Linking Infectious and Narcology Care in Russia
Conditions: HIV Infection;   Drug Use
Intervention: Behavioral: LINC Case Management
10 Recruiting Clinical Trial to Reduce Drinking in Women With HIV
Condition: HIV Infection
Interventions: Drug: Naltrexone;   Drug: Placebo
11 Enrolling by invitation HIV Disclosure and Medication Adherence, a Pilot Study
Condition: HIV Infection
Intervention:
12 Recruiting Metabolic Abnormalities in HIV-infected Persons
Conditions: Lipodystrophy;   HIV Infection
Interventions: Drug: Metformin;   Drug: Pioglitazone
13 Completed Darunavir Levels, Virological Efficacy, Proviral ADN and Resistances in Patients on Darunavir/Ritonavir Monotherapy
Condition: HIV-infection
Intervention: Drug: Darunavir/ritonavir
14 Enrolling by invitation Minority AIDS Initiative Retention and Re-Engagement Project
Condition: HIV/AIDS
Intervention: Behavioral: Enhanced Peer Intervention
15 Completed Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART
Condition: HIV-1 Infection
Interventions: Drug: Vacc-C5/GM-CSF;   Drug: Vacc-C5/Alhydrogel
16 Recruiting Evaluating the Response to Three Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 28 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
Condition: HIV Infections
Interventions: Drug: Lamivudine/zidovudine;   Drug: Lopinavir/ritonavir;   Drug: Efavirenz;   Drug: Raltegravir
17 Active, not recruiting Evaluation of Barriers to Postpartum Care in HIV Infected Women
Conditions: HIV Infection;   Pregnancy
Intervention: Other: questionaires and structured interviews
18 Completed A Study of Ritonavir-Boosted Invirase (Saquinavir) in Treatment-Naïve HIV-1 Infected Patients
Condition: HIV Infections
Interventions: Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTIs);   Drug: ritonavir;   Drug: saquinavir [Invirase]
19 Completed
Has Results
A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247)
Condition: HIV Infections
Interventions: Drug: Raltegravir;   Drug: TUMS® Ultra Strength;   Drug: MINTOX® Maximum Strength
20 Completed Evaluation of the Bioequivalence of a Combined Formulated Tablet
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg;   Drug: Dolutegravir 50 mg;   Drug: abacavir 600 mg/lamivudine 300 mg

Previous Page Studies Shown (1-20) Next Page (21-34) Show next page of results
Indicates status has not been verified in more than two years